Using Genetic Information to Help People Be Healthy at 100: Anne Wojcicki, CEO of 23andMe
Raise the Line
Discovering your ancestry through a DNA saliva test is commonplace and very popular today, but when 23andMe started offering the service to consumers in 2007, it was breaking new ground. “We started 23andMe with this mentality of being an activist brand. I want to empower people with their own genome. Then I want to empower people to essentially come together and be the world's largest community that's driving research forward,” says Anne Wojcicki, Co-founder and CEO of the company. In the past 14 years, she’s largely achieved that founding vision with 11.6 million people using the product and 80% of those consenting to have their information used in research. And, as Wojcicki tells host Shiv Gaglani, a trove of research papers and a constant stream of new genetic information is allowing 23andMe to move into developing therapeutics. The ultimate goal? “I want people to be able to use their genetic information to change their behavior and live to be 100 without any chronically-managed disease,” she says. Don’t miss this revealing discussion from a pioneer in direct-to-consumer healthcare about the impact of digital health, eliminating hierarchy in healthcare and the role providers can play in battling the swamp of medical misinformation. Spoiler: it might involve them learning to dance.
372: Biotech Billionaire Anne Wojcicki, Cofounder and CEO of 23andMe
Foundr Magazine Podcast with Nathan Chan
You’ve heard data has the power to make or break a business. Nobody knows this more than Anne Wojcicki, co-founder of biotech giant 23andMe. After 15 years of leveraging data to build a game-changing company, Wojcicki made headlines this summer when she became the latest self-made billionaire in the United States. In this episode of the Foundr podcast, learn how the newly minted billionaire built 23andMe from the ground up—plus what the company plans to do next with all that genomic data. Foundr’s Nathan Chan sat down to chat with Wojcicki about: The moment that inspired her to pursue “the solution to life” How she became the first woman to achieve billionaire status via a SPAC merger What it took to provide consumers with never-before-seen access to their genomic data The marketing plan that inspired customers to buy a product they didn’t know they needed How she grew her company from a tiny crew in a roof-less “office” to a team of more than 600 What 23andMe plans to do with the genomic data from 11.6 million people and counting And much more… fdsa Who do you want to see next on the podcast? Comment and let us know! And don't forget to leave us a 5-star review if you loved this episode. Wait, there's more… If you enjoy the Foundr podcast, check out our free trainings. Get exclusive, actionable advice from some of the world's best entrepreneurs. For more Foundr content, follow us on your favorite platform: Foundr.com Instagram YouTube Facebook Twitter LinkedIn Magazine
CEO Series: 23andMe’s Anne Wojcicki on Scientific Breakthroughs and Public Trust
Anne Wojcicki, CEO of 23andMe, spent a decade in healthcare and biotechnology before launching the DNA testing and analysis company in 2006. Her goal was twofold: to help individuals learn more about their own genetics, enabling them to pursue more personalized medical care, and to create a database of genetic information for commercial and academic researchers to promote broader improvements to the healthcare system. She speaks with HBR's Editor-in-Chief Adi Ignatius about tackling challenges in an emerging industry.
a16z Bio #7: The Power of Patient Data with Anne Wojcicki
On this episode of the a16z Bio Clubhouse Show, a16z general partners Vineeta Agarwala, Jorge Conde, Julie Yoo, and Vijay Pande, along with a16z cofounder Marc Andreessen, talk to guest Anne Wojcicki, CEO of 23andme. The conversation covers the shifting trends and perceptions at the intersection of bio and tech, the power of patient data and importance of giving people access to their own health data, and advice to founders on when to lead and when to listen.
Big Data, Long Lost Relatives, and Drug Development with Anne Wojcicki of 23andMe
The Two Percent
Anu and Anne Wojcicki, founder and CEO of 23andMe, discuss disrupting the drug development industry, COVID-19’s long term impact on digital health, bad-ass lesbian pirates, and why with data - there’s no such thing as taking a secret to the grave anymore.
Episode 24: Anne Wojcicki of 23andMe talks COVID-19 testing, your genes and the future of medicine
Fixing Healthcare Podcast
Anne Wojcicki is a biologist, entrepreneur and the CEO of 23andMe, the leading consumer genetics and research company with more than 12 million customers worldwide. On this episode, Wojcicki spoke with Dr. Robert Pearl and Jeremy Corr about exciting developments in genetic testing, the possibility for at-home coronavirus testing, her company’s fight with the FDA and what she believes will someday replace primary care. Here are some of the interview highlights from episode 24: On genetics and depression Thanks to the 450,000 customers who answered our surveys, where we were able to find a number of novel mutations associated with depression. Most studies are in the hundreds or maybe a thousand individuals, but for us to have a study of 450,000 people, it shows the type of scale of research that 23andMe can do and the fact that we can make findings that no one else really can find. On a genetic basis for the human response to COVID-19 23andMe launched a COVID-19 study on April 6, and we now have over 1 million people who’ve taken this survey. We have … tens of thousands who said that they have it, thousands of people who were hospitalized. We were able to make a number of discoveries. The only one that we’ve publicly talked about is the O blood type looks like it’s protective. Roughly, anywhere from 9% to 20% protective in terms of severity as well as susceptibility. That is exciting because I think it’s been replicated a number of times. On the next big breakthrough in genetics The next big breakthroughs are going to be around these polygenic risk scores and really starting to break down each disease into much more specific subtypes. Look at something like Type 2 diabetes where I can see that there’s a percentage of our customers that are genetically just much more likely to have it. You can see this also with drug response that some people are going to respond well to certain kinds of medications and some people are not going to respond well to those same medications. I think that every single disease is going to start to get classified into a genetically defined set of risks. On the medical benefits of DNA testing There’s no greater reward for me than knowing that we potentially prevented a preventable death … One of the mottos of the company is, “Change what you can, manage what you can’t,” and these cases where customers can learn that they have a potentially pathogenic mutation and there’s something that they can manage with a vasectomy or proactive screening and you can prevent a preventable death, it’s hugely rewarding. On how money is made in healthcare No one makes money in healthcare by keeping you healthy. Fundamentally, if I tell you, you’re diabetic, lots of people in the system, in the healthcare system as it is today, will make money, from the companies that make insulin to the needles to the testing to the doctor’s visits to all of the downstream consequences. If I tell you you’re genetically high risk for Type 2 diabetes and then you change your diet and you check in with your doctor and you’re like, “Yeah, I’ve lost weight. I’ve done this. I exercise more,” no one’s making money. On protecting consumer data online We’ve always said that we have no business if we can’t protect your privacy. We do everything we can reasonably to protect privacy … We were really lucky in that a number of our earliest engineers came from the banking industry and really came to us with a mindset of absolute privacy and choice and the highest level of security. READ: Full transcript of our discussion with Anne Wojcicki * * * Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple Podcasts or wherever you find podcasts. Join the conversation or suggest a guest by following the show on Twitter and LinkedIn. The post Episode 24: Anne Wojcicki of 23andMe talks COVID-19 testing, your genes and the future of medicine appeared first on Fixing Healthcare.
Anne Wojcicki on Direct-To-Consumer Healthcare and The Future of Digital Health
Village Global's Venture Stories
We are honored to have Anne Wojcicki (@annewoj23), co-founder and CEO of 23andMe, among our small group of luminary LPs whose financial capital and engagement power the next wave of Village Global founders.She joined us in Mountain View for an intimate fireside chat with the first Chief Data Scientist for the United States Office of Science and Technology Policy, DJ Patil (@dpatil).They discussed: - Why the US healthcare system is broken.- The state of direct-to-consumer healthcare.- Tailored medicine and the future of digital health.- 23andMe’s drug discovery efforts and how continuous data monitoring can change how drugs are developed.- The problem with clinical trials and how to fix them.- How Anne would change the US healthcare system if she could wave a magic wand.- The founding of 23andMe and the company’s philosophy.Thanks for listening — if you like what you hear, please review us on your favorite podcast platform. Check us out on the web at villageglobal.vc or get in touch with us on Twitter @villageglobal.Venture Stories is brought to you by Village Global, is hosted by co-founder and partner, Erik Torenberg and is produced by Brett Bolkowy.
43. 23andMe's Anne Wojcicki: Embrace the gatekeepers
Masters of Scale with Reid Hoffman